Burden for Parents of Patients With Schizophrenia-A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls.


Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
18 06 2019
Historique:
pubmed: 6 9 2018
medline: 1 7 2020
entrez: 6 9 2018
Statut: ppublish

Résumé

The study aimed to (1) compare the risk of health care use, adverse health status, and work productivity loss of parents of patients with schizophrenia to parents of patients with multiple sclerosis (MS), rheumatoid arthritis (RA), epilepsy, and healthy controls; and (2) evaluate such outcome measures while considering disease severity of schizophrenia. Based on linkage of Swedish registers, at least one parent was included (n = 18215) of patients with schizophrenia (information 2006-2013, n = 10883). Similarly, parental information was linked to patients with MS, RA, epilepsy, and matched healthy controls, comprising 11292, 15516, 34715, and 18408 parents, respectively. Disease severity of schizophrenia was analyzed. Different regression models yielding odds ratios (OR), hazard ratios (HR), or relative risks (RR) with 95% confidence intervals (CI) were run. Psychiatric health care use, mainly due to anxiety and affective disorders, showed a strongly increasing trend for parents of patients with schizophrenia throughout the observation period. During the follow-up, these parents had an up to 2.7 times higher risk of specialized psychiatric health care and receipt of social welfare benefits than other parents. Parents of the moderately severely ill patients with schizophrenia had higher risk estimates for psychiatric health care (RR: 1.12; 95% CI: 1.07-1.17) compared with parents of least severely ill patients. Parents of patients with schizophrenia have a considerably higher risk of psychiatric health care and social welfare benefit receipt than other parents. Psychiatric health care use worsens over time and with increasing disease severity of the offspring.

Sections du résumé

BACKGROUND
The study aimed to (1) compare the risk of health care use, adverse health status, and work productivity loss of parents of patients with schizophrenia to parents of patients with multiple sclerosis (MS), rheumatoid arthritis (RA), epilepsy, and healthy controls; and (2) evaluate such outcome measures while considering disease severity of schizophrenia.
METHODS
Based on linkage of Swedish registers, at least one parent was included (n = 18215) of patients with schizophrenia (information 2006-2013, n = 10883). Similarly, parental information was linked to patients with MS, RA, epilepsy, and matched healthy controls, comprising 11292, 15516, 34715, and 18408 parents, respectively. Disease severity of schizophrenia was analyzed. Different regression models yielding odds ratios (OR), hazard ratios (HR), or relative risks (RR) with 95% confidence intervals (CI) were run.
RESULTS
Psychiatric health care use, mainly due to anxiety and affective disorders, showed a strongly increasing trend for parents of patients with schizophrenia throughout the observation period. During the follow-up, these parents had an up to 2.7 times higher risk of specialized psychiatric health care and receipt of social welfare benefits than other parents. Parents of the moderately severely ill patients with schizophrenia had higher risk estimates for psychiatric health care (RR: 1.12; 95% CI: 1.07-1.17) compared with parents of least severely ill patients.
CONCLUSIONS
Parents of patients with schizophrenia have a considerably higher risk of psychiatric health care and social welfare benefit receipt than other parents. Psychiatric health care use worsens over time and with increasing disease severity of the offspring.

Identifiants

pubmed: 30184197
pii: 5090132
doi: 10.1093/schbul/sby130
pmc: PMC6581137
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

794-803

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Schizophr Res Treatment. 2014;2014:368215
pubmed: 24864209
Int J Soc Psychiatry. 2015 Feb;61(1):10-6
pubmed: 24869849
J Nerv Ment Dis. 2002 Apr;190(4):241-7
pubmed: 11960085
Psychiatry Res. 2008 Apr 15;158(3):335-43
pubmed: 18280584
Clinicoecon Outcomes Res. 2015 Nov 25;7:593-602
pubmed: 26648745
Aust N Z J Psychiatry. 1998 Oct;32(5):673-9
pubmed: 9805590
Biomater Sci. 2017 Jul 25;5(8):1407-1420
pubmed: 28631779
Br J Psychiatry Suppl. 2007 Aug;50:s29-36
pubmed: 18019041
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Nat Rev Neurol. 2015 Mar;11(3):134-42
pubmed: 25686758
J Nerv Ment Dis. 2009 May;197(5):298-304
pubmed: 19440101
Epidemiol Rev. 2008;30:67-76
pubmed: 18480098
Health Econ. 2013 Oct;22(10):1230-49
pubmed: 23225741
Prog Biophys Mol Biol. 2015 Jul;118(1-2):1-7
pubmed: 25958205
Acta Psychiatr Scand Suppl. 2007;(437):66-76
pubmed: 17973811
Nurs Child Young People. 2016 May 9;28(4):75
pubmed: 27214444
Curr Psychiatry Rep. 2017 Jan;19(1):2
pubmed: 28097634
Pharmacoeconomics. 2008;26(2):149-62
pubmed: 18198934
Harv Rev Psychiatry. 2012 May-Jun;20(3):119-29
pubmed: 22716503
Eur Neuropsychopharmacol. 2018 Mar;28(3):436-443
pubmed: 29275842
Int J Soc Psychiatry. 2013 Mar;59(2):137-46
pubmed: 22100570
Brain. 2014 Mar;137(Pt 3):770-8
pubmed: 24441172
Epilepsia. 2015 Sep;56(9):1388-97
pubmed: 26235849
World J Psychiatry. 2012 Jun 22;2(3):43-8
pubmed: 24175167
Trends Psychiatry Psychother. 2016 Apr-Jun;38(2):96-9
pubmed: 27409135
BMJ. 2014 Feb 12;348:g1173
pubmed: 24523363
Int J Soc Psychiatry. 2015 Nov;61(7):684-92
pubmed: 25770207
Indian J Psychol Med. 2013 Apr;35(2):135-40
pubmed: 24049223
Indian J Psychol Med. 2013 Jul;35(3):251-5
pubmed: 24249926
JAMA. 1999 Dec 15;282(23):2215-9
pubmed: 10605972
Nord J Psychiatry. 2016;70(4):248-54
pubmed: 26524243
Psicothema. 2014 May;26(2):235-43
pubmed: 24755026
BMC Psychiatry. 2015 Jul 21;15:162
pubmed: 26194890
Soc Psychiatry Psychiatr Epidemiol. 2010 Feb;45(2):275-83
pubmed: 19452109
Neuropsychiatr Dis Treat. 2015 Jan 14;11:145-51
pubmed: 25609970
Psychol Bull. 2003 Nov;129(6):946-72
pubmed: 14599289
Health Psychol. 2017 Aug;36(8):770-778
pubmed: 28639819
Eur Psychiatry. 2004 Nov;19(7):408-14
pubmed: 15504647
Scand J Soc Med. 1991 Sep;19(3):148-53
pubmed: 1796246
J Neurol. 2014 Oct;261(10):2037-42
pubmed: 25182699
Health Qual Life Outcomes. 2009 Sep 11;7:84
pubmed: 19747384
Nat Rev Dis Primers. 2015 Nov 12;1:15067
pubmed: 27189524
Arthritis Rheum. 2004 Aug 15;51(4):570-7
pubmed: 15334429
Phys Med Rehabil Clin N Am. 2013 Nov;24(4):619-27
pubmed: 24314680
J Clin Psychiatry. 2007 Jun;68(6):818-25
pubmed: 17592904
Am J Med Genet B Neuropsychiatr Genet. 2018 Mar;177(2):242-256
pubmed: 29442441
Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49
pubmed: 15133589
Epilepsy Res Treat. 2014;2014:808421
pubmed: 24808956
Neurosci Biobehav Rev. 2017 Feb;73:123-164
pubmed: 27986469
Brain. 2014 Oct;137(Pt 10):2680-9
pubmed: 25063994
Aging Ment Health. 2012;16(6):673-4
pubmed: 22746192
Cochrane Database Syst Rev. 2014 Mar 05;(3):CD009802
pubmed: 24595545
Cell Biochem Biophys. 2015 Sep;73(1):7-10
pubmed: 25701951
Psychol Health. 2016 Jun;31(6):693-710
pubmed: 26742505
Qual Life Res. 2013 Aug;22(6):1265-72
pubmed: 22907603
Arthritis Rheum. 2013 Nov;65(11):2773-82
pubmed: 23897126
Clin Rheumatol. 2011 Mar;30 Suppl 1:S3-8
pubmed: 21359507
J Am Med Dir Assoc. 2017 Feb 1;18(2):111-116
pubmed: 27742585
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216

Auteurs

Ellenor Mittendorfer-Rutz (E)

Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Syed Rahman (S)

Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Antti Tanskanen (A)

Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland.
The Impact Assessment Unit, National Institute for Health and Welfare, Helsinki, Finland.

Maila Majak (M)

EPID Research Oy, Espoo, Finland.

Juha Mehtälä (J)

EPID Research Oy, Espoo, Finland.

Fabian Hoti (F)

EPID Research Oy, Espoo, Finland.

Erik Jedenius (E)

Janssen Cilag, Sweden.

Dana Enkusson (D)

Janssen Cilag, Sweden.

Amy Leval (A)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Jan Sermon (J)

Janssen Cilag, Beerse, Belgium.

Heidi Taipale (H)

Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
School of Pharmacy, University of Eastern Finland, Kuopio, Finland.

Jari Tiihonen (J)

Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH